Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Nature of Business and Significant Accounting Policies (Details Narrative)

Nature of Business and Significant Accounting Policies (Details Narrative) $ in Thousands		12 Months Ended
	Jan. 15, 2020	Dec. 31, 2019 USD ($) Segment	Jan. 02, 2019 USD ($)
Number of reportable segments \| Segment		1
Reduction of revenues		$ 3,500
ASU Topic 606 [Member]
Cumulative catch-up adjustment under modified retrospective method			$ 2,500
Minimum [Member]
Finite-lived intangible asset, useful life		2 years
Maximum [Member]
Finite-lived intangible asset, useful life		9 years
Furniture and Fixtures [Member] \| Minimum [Member]
Property, plant and equipment, useful life		7 years
Furniture and Fixtures [Member] \| Maximum [Member]
Property, plant and equipment, useful life		10 years
Office and Computer Equipment [Member] \| Minimum [Member]
Property, plant and equipment, useful life		2 years
Office and Computer Equipment [Member] \| Maximum [Member]
Property, plant and equipment, useful life		5 years
Lab Equipment [Member] \| Minimum [Member]
Property, plant and equipment, useful life		3 years
Lab Equipment [Member] \| Maximum [Member]
Property, plant and equipment, useful life		7 years
Leasehold Improvements [Member] \| Minimum [Member]
Property, plant and equipment, useful life		4 years
Leasehold Improvements [Member] \| Maximum [Member]
Property, plant and equipment, useful life		5 years
Software for Internal Use [Member] \| Minimum [Member]
Property, plant and equipment, useful life		3 years
Software for Internal Use [Member] \| Maximum [Member]
Property, plant and equipment, useful life		7 years
Software for External Use [Member]
Property, plant and equipment, useful life		3 years
Subsequent Event [Member]
Decreased issued and outstanding description	The Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the "Reverse Stock Split"). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. The Company's issued and outstanding stock decreased from 39,205,895 to 3,920,589 and 28,694,275 to 2,869,427 at December 31, 2019 and 2018, respectively.